Seattle Genetics Inc (SGEN)

61.74
NASDAQ : Health Care
Prev Close 63.25
Day Low/High 61.29 / 63.32
52 Wk Low/High 35.93 / 75.36
Avg Volume 723.10K
Exchange NASDAQ
Shares Outstanding 142.72M
Market Cap 9.03B
EPS -1.00
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Seattle Genetics Discontinues Phase 3 CASCADE Trial Of Vadastuximab Talirine (SGN-CD33A) In Frontline Acute Myeloid Leukemia

Seattle Genetics, Inc. (Nasdaq: SGEN), a global biotechnology company, today announced that it is discontinuing the phase 3 CASCADE clinical trial of vadastuximab talirine (SGN-CD33A) in frontline older acute myeloid...

Seattle Genetics And Bristol-Myers Squibb Highlight Interim Phase 1/2 Data Evaluating Combination Of ADCETRIS® (Brentuximab Vedotin) And Opdivo® (Nivolumab) In Relapsed Hodgkin Lymphoma At The International Conference On Malignant Lymphoma

Seattle Genetics, Inc. (Nasdaq: SGEN) and Bristol-Myers Squibb Company (NYSE: BMY) today highlighted an updated interim analysis from the ongoing phase 1/2 clinical trial evaluating ADCETRIS (brentuximab vedotin)...

Apple Could Explode Higher to $200 a Share If This Chart Pattern Is Correct

Apple Could Explode Higher to $200 a Share If This Chart Pattern Is Correct

Huge profits could be on the doorstep for these hot breakout setups.

Seattle Genetics And Astellas Announce Updated Enfortumab Vedotin Phase 1 Data In Metastatic Urothelial Cancer At 2017 ASCO Annual Meeting

Seattle Genetics, Inc. (NASDAQ: SGEN) and Astellas today highlighted updated phase 1 data for enfortumab vedotin (ASG-22ME) studied as monotherapy treatment for metastatic urothelial cancer (mUC) in an oral...

Analysts' Actions -- Costco, J.C. Penney, Cisco, TherapeuticsMD and More

Analysts' Actions -- Costco, J.C. Penney, Cisco, TherapeuticsMD and More

Here are Tuesday's top research calls, including downgrades for Cisco Systems and TherapeuticsMD, and new coverage of Costco and J.C. Penney.

Seattle Genetics To Present At Bank Of America Merrill Lynch 2017 Healthcare Conference

Seattle Genetics, Inc. (NASDAQ:SGEN) announced today that management will present at the Bank of America Merrill Lynch 2017 Healthcare Conference on Tuesday, May 16 at 9:20 a.

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,200 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: AOSL, AVD, BCC, BGSF, CDR, CTRE, DV, LUK, PHX, PRLB, RTIX, SFM, STAY, TRP, WAGE, ZAGG Downgrades: ABCO, ACIW, AMAG, CQP, HDNG, INT, NEWM, RGS, SGEN, SSP, TAC Initiations: None Read on to get TheStreet Quant Ratings' detailed report:

Immunomedics, Seattle Genetics Scrap License Deal

Immunomedics, Seattle Genetics Scrap License Deal

Delaware Vice Chancellor J. Travis Laster in March halted the deal as a result of a lawsuit filed by VenBio Partners, an activist firm invested in Immunomedics.

Biotech Movers: Immunomedics Shares Jump After License Pact with Seattle Genetics Is Terminated

Biotech Movers: Immunomedics Shares Jump After License Pact with Seattle Genetics Is Terminated

Immunomedics and Seattle Genetics have agreed to terminate the license pact that was first announced in February.

Seattle Genetics Terminates License Agreement With Immunomedics For Sacituzumab Govitecan (IMMU-132)

Seattle Genetics, Inc. (Nasdaq: SGEN), a global biotechnology company, today announced that it has agreed to terminate its license agreement with Immunomedics, Inc.

Seattle Genetics Reports First Quarter 2017 Financial Results

Seattle Genetics, Inc. (NASDAQ: SGEN), a global biotechnology company, today reported financial results for the first quarter ended March 31, 2017.

Seattle Genetics To Host Conference Call And Webcast Discussion Of First Quarter Financial Results On April 27, 2017

Seattle Genetics, Inc. (Nasdaq: SGEN) announced today that it will report its first quarter financial results on Thursday, April 27, 2017, after the close of financial markets.

Seattle Genetics Presents Data Advancing Antibody-Drug Conjugate And Novel Immuno-Oncology Programs At The American Association For Cancer Research (AACR) Annual Meeting

Seattle Genetics, Inc. (Nasdaq: SGEN), a global biotechnology company, today highlighted multiple data presentations that support the company's advancing antibody-drug conjugate (ADC) and immuno-oncology programs at...

Seattle Genetics Highlights Leadership In Antibody-Drug Conjugate Technology Innovation At The American Association For Cancer Research (AACR) Annual Meeting

Seattle Genetics, Inc. (Nasdaq: SGEN), a global biotechnology company, today announced its broad presence at the upcoming 108 th Annual Meeting of the American Association for Cancer Research (AACR) being held April...

12 Years and Still Finding the Bulls for You: Cramer's 'Mad Money' Recap (Tuesday 3/14/17)

12 Years and Still Finding the Bulls for You: Cramer's 'Mad Money' Recap (Tuesday 3/14/17)

Jim Cramer says it's his job to educate and entertain you, as well as help you make and save money.

Cisco Systems, CyberArk, Check Point Software: 'Mad Money' Lightning Round

Cisco Systems, CyberArk, Check Point Software: 'Mad Money' Lightning Round

Jim Cramer is bullish on Cisco Systems, Check Point Software and CyberArk Software.

Immunomedics Soars on Injunction Against Seattle Genetics Deal

Immunomedics Soars on Injunction Against Seattle Genetics Deal

The biotech company embattled by activist investor VenBio may not be able to go through with its licensing deal.

FDA Lifts Clinical Hold On Seattle Genetics' Phase 1 Trials Of Vadastuximab Talirine

Seattle Genetics, Inc. (Nasdaq:SGEN), a global biotechnology company, today announced that the U.

Activist Investor Wins Control of Immunomedics Board Following Shareholder Vote

Activist Investor Wins Control of Immunomedics Board Following Shareholder Vote

The newly reconstituted Immunomedics board is likely to start a search for a new CEO and could either renegotiate the IMMU-132 deal with Seattle Genetics or cancel it.

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders Of Seattle Genetics Inc. Of A Class Action Lawsuit And A Lead Plaintiff Deadline Of March 13, 2017

The following statement is being issued by Levi & Korsinsky, LLP: To: All persons or entities who purchased or otherwise acquired securities of Seattle Genetics Inc.

Seattle Genetics To Present At Upcoming Investor Conferences

Seattle Genetics, Inc. (NASDAQ:SGEN) announced today that management will present at the following upcoming investor conferences.

SGEN SHAREHOLDER ALERT: The Law Offices Of Vincent Wong Reminds Investors Of A Class Action Involving Seattle Genetics Inc. And A Lead Plaintiff Deadline Of March 13, 2017

The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the Western District of Washington on behalf of investors who purchased Seattle Genetics Inc.